Glenmark Pharmaceuticals
Bernard Munos is a pharmaceutical executive and director who has spent their career in the industry researching and developing new treatments. Bernard is currently the Director at Glenmark Pharmaceuticals. Prior to this, they were a Scientist at Science.com, and before that, they held positions at Stellate Therapeutics (formerly Amabiotics), AsedaSciences, Open Source Pharma Foundation, and University of California, San Francisco. In addition to their work in the pharmaceutical industry, Bernard has also been involved with the Milken Institute's FasterCures organization and the InnoThink Center for Research in Biomedical Innovation.
Bernard Munos has an MBA from Stanford University Graduate School of Business, an MS from University of California, Davis, and an M.Sc. Eng. from AgroParisTech - Institute of Technology for Life, Food and Environmental Sciences. Bernard also has executive education in corporate valuation from Harvard Business School.
This person is not in the org chart
This person is not in any offices
Glenmark Pharmaceuticals
5 followers
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.